JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD B. Pharmacy III Year MEDICINAL CHEMISTRY-I Previous Question Paper (September-2021 - R17)

The biological activity of a drug molecule is fundamentally determined by its physicochemical properties, which govern its transport, distribution, and interaction with biological receptors. These properties dictate how a drug reaches its target site and the strength of the resulting pharmacological effect.

Key physicochemical properties include:

1. Solubility and Partition Coefficient (Log P): Drugs must possess an optimal balance of hydrophilicity and lipophilicity. The partition coefficient measures the distribution of a drug between lipid and aqueous phases. High lipophilicity aids membrane permeation, while sufficient hydrophilicity ensures solubility in body fluids.
2. Ionization (pKa): Most drugs are weak acids or bases. The degree of ionization at physiological pH (e.g., 7.4 in blood) determines the ratio of ionized to unionized forms. The unionized form is generally more lipophilic and capable of crossing biological membranes, whereas the ionized form is often required for binding to receptors via ionic interactions.
3. Hydrogen Bonding: The ability of a drug to act as a hydrogen bond donor or acceptor is critical for receptor binding and solubility. These interactions provide specificity and stability to the drug-receptor complex.
4. Molecular Weight and Size: Smaller molecules generally exhibit better membrane permeability. Extremely large molecules may face steric hindrance, preventing them from accessing specific binding pockets.
5. Stereochemistry: Optical and geometric isomers often exhibit vastly different biological activities. Receptors are chiral, meaning they can distinguish between enantiomers, where one may be highly potent while the other is inactive or toxic.
6. Electronic Effects: The distribution of electrons within a molecule, influenced by inductive and resonance effects, determines the reactivity of the drug and its ability to form covalent or non-covalent bonds with target macromolecules.

In summary, the Hansch analysis and other quantitative structure-activity relationship (QSAR) models demonstrate that biological response is a function of these physicochemical parameters. Optimizing these properties is essential during drug design to ensure favorable pharmacokinetics and pharmacodynamics.

Drug metabolism is the process of chemical modification of drugs by enzymes, primarily in the liver, to facilitate their excretion. Several factors influence the rate and extent of these metabolic pathways, which can be categorized as follows:

1. Chemical Factors: The chemical structure of a drug determines its susceptibility to metabolic enzymes. Factors include lipophilicity, molecular size, and the presence of specific functional groups (e.g., hydroxyl, amino, or carboxyl groups) that serve as sites for conjugation or oxidation.

2. Biological Factors:

• Species and Strain Differences: Variations in the quantity and quality of enzymes (e.g., Cytochrome P450 isoforms) lead to species-specific metabolic profiles.
• Age: Neonates often have immature enzyme systems, while the elderly may experience reduced hepatic blood flow and enzyme activity, affecting drug clearance.
• Sex: Hormonal differences (e.g., androgens and estrogens) can influence the expression of specific metabolic enzymes, leading to gender-based differences in drug metabolism.
• Genetic Factors: Genetic polymorphisms in enzymes like CYP2D6 or CYP2C19 result in phenotypes such as poor, intermediate, extensive, or ultra-rapid metabolizers.

3. Environmental and Dietary Factors: Exposure to enzyme inducers (e.g., cigarette smoke, polycyclic aromatic hydrocarbons) or inhibitors (e.g., grapefruit juice, certain medications) can significantly alter the rate of metabolism. Nutritional status, such as protein deficiency, can also impair the synthesis of metabolic enzymes.

4. Stereochemical Aspects: Stereochemistry plays a critical role in drug metabolism because enzymes are chiral and exhibit high substrate specificity. Enantiomers of a racemic drug often undergo different metabolic pathways or rates of metabolism:

• Stereoselective Metabolism: Enzymes may show a preference for one enantiomer over the other, leading to different plasma concentrations of the active drug.
• Stereospecificity: The orientation of functional groups in space determines how well a drug molecule fits into the active site of an enzyme. A change in configuration can result in a drug being a substrate, an inhibitor, or completely resistant to a particular enzyme.
• Chiral Inversion: Some drugs undergo metabolic inversion, where one enantiomer is converted into the other (e.g., the inversion of R-ibuprofen to S-ibuprofen), which can complicate the pharmacological profile of the drug.